Get the Stockscreener App
3.44
0.29%
0.010
Camp 4 Therapeutics Corp stock is traded at $3.44, with a volume of 24,428.
It is up +0.29% in the last 24 hours and down -17.90% over the past month.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
See More
Previous Close:
$3.43
Open:
$3.46
24h Volume:
24,428
Relative Volume:
0.07
Market Cap:
$215.87M
Revenue:
$3.50M
Net Income/Loss:
$-80.40M
P/E Ratio:
-1.3379
EPS:
-2.5711
Net Cash Flow:
$-29.83M
1W Performance:
-7.03%
1M Performance:
-17.90%
6M Performance:
-25.05%
1Y Performance:
+0.00%
1-Day Range:
$3.43
$3.54
1-Week Range:
$3.17
$3.87
52-Week Range:
$2.86
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.44 | 215.87M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
508.54 | 128.90B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.85 | 94.96B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.52 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.03 | 53.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Initiated | Oppenheimer | Outperform |
| Jun-16-26 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-26 | Initiated | Chardan Capital Markets | Buy |
| Apr-14-26 | Initiated | Rodman & Renshaw | Buy |
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference - GlobeNewswire Inc.
CAMP4 Therapeutics CorporationCommon Stock (Nasdaq:CAMP) Stock Quote - FinancialContent
Form 8K Camp4 Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa
Form 8K Camp4 Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Camp4 Therapeutics (Nasdaq:CAMP)Stock Analysis - Simply Wall Street
CAMP4 receives UK approval for CMP-002 trial sites - grafa.com
CAMP4 Therapeutics Receives MHRA Authorization to Include UK Sites in Global Phase 1/2 Trial of CMP-002 for SYNGAP1-Related Disorder - Quiver Quantitative
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder - Yahoo Finance
A potential treatment for a genetic disorder is expected to enter human testing late in 2026. CAMP4 will discuss it Sept. 28. - Stock Titan
Camp4 CFO Kelly Gold buys $39,600 in company stock By Investing.com - Investing.com India
Camp4 CFO Kelly Gold buys $39,600 in company stock By Investing.com - Investing.com Canada
Camp4 CFO Kelly Gold buys $39,600 in company stock - investing.com
CAMP4 to Participate in Upcoming Investor Conferences - GlobeNewswire
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock By Investing.com - Investing.com South Africa
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock By Investing.com - Investing.com Australia
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock By Investing.com - Investing.com Nigeria
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock - investing.com
5AM nears 10% cap in Camp4 Therapeutics (CAMP) while unloading shares - Stock Titan
Camp4 Therapeutics director Andrew Schwab sells $45 in shares By Investing.com - Investing.com Canada
Camp4 Therapeutics Corp presents new approach to treat haploinsufficient diseases via SYNGAP program - Traders Union
Balyasny Asset Management L.P. Reduces Stake in Camp4 Therapeuti - GuruFocus
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Australia
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Nigeria
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com South Africa
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock - Investing.com
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Canada
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock - Investing.com
Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales - Stock Titan
Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares - Stock Titan
ETFs Investing in CAMP4 Therapeutics Corporation Stocks - TradingView
Analysts’ Top NA Picks: CAMP4 Therapeutics Corporation (CAMP), Wayfair (W) - The Globe and Mail
CAMP4 Therapeutics (CAMP) Jumps 8% to $4.86: Key Levels to WatchMomentum Stock Picks - vinanet.vn
Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates - scanx.trade
CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges - Stock Titan
CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028 - Stock Titan
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026) - Stock Titan
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares - Stock Titan
CAMP4 Therapeutics Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView
CAMP Q1 2026 Earnings: EPS Miss Deepens 49.4% as Pre-Revenue Biotech Navigates Pipeline ProgressEarnings Surprise Stocks - vinanet.vn
Camp4 Therapeutics Corp CEO to launch new SYNGAP1 clinical trial in upcoming initiative - Traders Union
Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Purchases 6,551 Shares - MarketBeat
Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Buys $10,809.15 in Stock - MarketBeat
5AM Ventures group updates CAMP4 Therapeutics (CAMP) stake and warrant terms - Stock Titan
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 27 '26 |
Sale |
4.04 |
400,000 |
1,616,000 |
2,033,270 |
| Schwab Andrew J. | Director |
Aug 24 '26 |
Sale |
4.50 |
10 |
45 |
2,433,270 |
| Schwab Andrew J. | Director |
Aug 21 '26 |
Sale |
4.50 |
32,018 |
144,081 |
2,433,280 |
| Schwab Andrew J. | Director |
Aug 20 '26 |
Sale |
4.54 |
114,700 |
520,738 |
2,465,298 |
| Tardiff Daniel | Chief Scientific Officer |
Aug 19 '26 |
Sale |
4.76 |
1,738 |
8,273 |
0 |
| Schwab Andrew J. | Director |
Aug 19 '26 |
Sale |
4.76 |
45,147 |
214,900 |
2,579,998 |
| Daniel Tardiff | affiliate |
Aug 19 '26 |
Proposed Sale |
4.76 |
1,738 |
8,276 |
0 |
| Young Richard A | Director |
Aug 03 '26 |
Buy |
1.65 |
16,378 |
27,024 |
186,388 |
| Maricich Yuri | Chief Medical Officer |
Aug 03 '26 |
Buy |
1.65 |
6,551 |
10,809 |
12,611 |
| Gold Kelly | Chief Financial Officer |
Aug 03 '26 |
Buy |
1.65 |
6,551 |
10,809 |
74,428 |
3.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):